Effect of add on therapy of SGLT 2 inhibitors on glycaemic parameters


  • Subashini Shanmuganandam Department of Pharmacology, St Peters Medical College Hospital and Research Institute, Hosur, Tamil Nadu, India
  • Manjula M. J. Department of Pharmacology, RRMCH, Bangalore, Karnataka, India




Gliflozins, Glycosuria, HbA1c, Type 2 diabetes mellitus, Weight loss


Background: Glycaemic control in type 2 diabetes mellitus can be difficult to attain, even with a combination of multiple oral agents as well as Insulin. SGLT2 inhibitors are potential novel agents inhibits the sodium glucose co transporters operated in the kidney tubules independent of the action on insulin resistance or secretion. This study aimed to evaluate the effect on the mean reduction of HbA1c levels. Also, to evaluate the effect of gliflozins on the mean reduction of FBS and PPBS values at the end of 3rd and 6th months and to find out the ADR profile over 6 months.

Methods: Prospective observational study conducted on the patients with type 2 diabetes mellitus with HbA1c >7% not controlled on metformin in the outpatient over a period of 15 months. An initial visit and thereafter follow up visits at 3rd and 6th month. HbA1c, FBS and PPBS was noted. ADR profile was also noted.

Results: Significant mean reduction in the glycemic parameters among 90% study population with 0.5% reduction in mean HbA1c from the baseline. Also, the reduction in FBS and PPBS were statistically significant by 3rd month of the treatment. Incidence of genital itching was more compared with conventional drugs. Hypotension and polydipsia were rare.

Conclusions: SGLT 2 inhibitors are found to be a promising new category of antidiabetic medications with better control of FBS, PPBS and HbA1c.


Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Ind J Ophthalmol. 2021;69(11):2932-8.

Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71:816-24.

Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354-95.

Zhao Q, Hong D, Zheng D, Xiao Y, Wu B. Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. Drug Des Devel Ther. 2014;8:2283-94.

Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care. 2014;37(6):1499-508.

Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-42.

Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. cardiovascular and kidney effects, potential mechanisms, and clinical applications. AHA Circulation. 2016;134(10):752-72.

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-9.

Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R. Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. Ther Clin Risk Manag. 2017;13:603-611.

Abdul-Ghani M, DeFronzo R. Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option? Ann Transl Med. 2018;6(2):S95.

Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mole Sci. 2019;20(3):629.

Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Therapy. 2020;11:2757-74.

Rosenstock J, Vico M, Wei LI, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diab Care. 2012;35(7):1473-8.

Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ open. 2012;2(5).

Van Bommel EJ, Muskiet MH, van Baar MJ, Tonneijck L, Smits MM, Emanuel AL, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Inter. 2020;97(1):202-12




How to Cite

Shanmuganandam, S., & M. J., M. (2024). Effect of add on therapy of SGLT 2 inhibitors on glycaemic parameters. International Journal of Basic & Clinical Pharmacology, 13(3), 333–338. https://doi.org/10.18203/2319-2003.ijbcp20240988



Original Research Articles